Injections "Mildronate" contribute to the inhibition of y-butyrobetaine-hydroxylase, provoke a decrease in the level of free carnitine, reduce carnitine-dependent oxidation of fatty acids. The drug improves metabolic processes, increases efficiency, reduces the manifestation of physical and mental overstrain. The tool also has a cardioprotective effect.
The drug "Mildronate" (intramuscularly) contributes to the regulation of cellular immunity, eliminates disorders in the nervous system of a functional nature in those suffering from chronic alcoholism on the background of withdrawal syndrome. The drug is involved in the redistribution of blood flow to ischemic areas, namely in the retina and brain.
The drug "Mildronate" (intramuscularly) is prescribed for reduced performance, physical overstrain, including athletes. The drug is recommended in the complex therapy of coronary artery disease (angina pectoris, chronic insufficiency, heart attack and dyshormonal cardiopathy), with withdrawal syndrome against the background of chronic alcoholism (in combination with specific therapy). The medicine "Mildronate" (intramuscularly) is also used for disorders (chronic and acute) of cerebral blood supply, i.e. in the treatment of cerebralstrokes and chronic insufficiency. In these cases, the drug is used as part of complex therapy.
The drug has a half-life of three to six hours.
In chronic alcoholism, the drug "Mildronate" (intramuscularly) is recommended twice a day for half a gram, daily for seven or ten days.
For mental and physical overload, the drug is recommended for adult patients orally four times a day, 0.25 grams or intravenously 0.5 grams once a day. The duration of therapy is from ten to fourteen days. If necessary, a second course is recommended after two to three weeks. Athletes are prescribed orally twice a day before training, 0.5-1 gram. During the preparatory period, the duration of the course is fourteen to twenty-one days, and during the competition, ten to fourteen days.
In case of cerebrovascular insufficiency in the acute phase of cerebrovascular pathology, five milliliters of a ten percent solution are administered intravenously daily for ten days. Further, the medicine is prescribed orally for half a gram daily. The duration of therapy is two or three weeks.
The drug "Mildronate" (analogues of the drug, for example, the drug "Carnitine") is contraindicated in hypersensitivity and organic CNS lesions.
Dyspeptic symptoms, itching, psychomotor agitation, tachycardia, changes in blood pressure are noted when using the medicine.
Not installedsafety of the drug during pregnancy. In this regard, the remedy "Mildronate" (intramuscularly, intravenously and orally) is not prescribed. If necessary, use the drug during lactation, it is recommended to stop feeding.
